Page 5 - Priority Review News Today

May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration granted Priority Review for the supplemental Biologics...

Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended...

The new formulation was approved to help patients with tardive dyskinesia who have trouble swallowing.

Net product revenues for the first quarter 2024 totaled $359.5 million, a 55% increase over the same quarter of the prior year ELEVIDYS net revenues for the quarter totaled $133.9...

FDA approves label update for voclosporin (Lupkynis) in lupus nephritis, reflecting long-term AURORA data and new kidney function monitoring guidance.

– Total revenues of $881 million in the first quarter – Jakafi® net product revenues of $572 million in Q124, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of...

The phase 3 STRIDE-10 trial evaluated the safety and immunogenicity of V116 in pneumococcal vaccine-naive adults 50 years of age and older.

In this article, we will take a look at the 11 oversold growth stocks to buy right now.

By Chris Wack X4 Pharmaceuticals said that the Food and Drug Administration approved Xolremdi capsules for use in patients 12 years of age and older with WHIM syndrome to increase the number...

In this article, we will take a look at the 11 oversold growth stocks to buy right now. To skip our analysis of the recent trends and market activity, you can go directly to see the 5 Oversold Growth Stocks to Buy Right Now. Growth is a highly sought after phenomenon whether it pertains to […]